Skip to content
Screener

Corcept Therapeutics CORT Q2 2026 earnings

Reported July 29, 2026 · After market close

Revenue$256.1MBeat by $35.0M
EPS$0.36Beat by $0.34
Revenue estimate$221.1M
EPS estimate$0.02

Next report

Nov 4, 2026 (in a month)
Revenue estimate$323.9M
EPS estimate$0.81

Financials

Q2 2026

Income statement

See full
Revenue$256.1M+31.7%
Gross profit$252.1M+32.0%
Operating income$41.3M+54.8%
Net income$43.0M+22.3%
EPS (diluted)$0.36+24.1%

Balance sheet

See full
Cash & equivalents$112.3M+9.3%
Total debt$9.4M+42.6%
Total equity$705.8M+11.0%
Total assets$888.7M+10.8%

Cash flow

See full
Operating cash flow$33.5M-23.7%
CapEx$2.5M+4,335%
Free cash flow$31.0M-29.3%

Valuation & ratios

Valuation

as of 10/02/26
See full
Market cap$12.33B+36.8%
Enterprise value$12.22B+37.5%
P/E223.4×+138×
P/S14.8×+2.7×

Profitability

See full
Gross margin98.3%-0.1pp
Operating margin0.8%-13.5pp
Net margin6.6%-12.0pp
FCF margin12.9%-12.3pp

Returns & leverage

See full
Return on equity8.2%-13.5pp
Debt / equity0×0.0×
Current ratio2.9×-0.2×

FAQ

When did Corcept Therapeutics report Q2 2026 earnings?
Corcept Therapeutics (CORT) reported Q2 2026 earnings on July 29, 2026 after market close.
What were Corcept Therapeutics's Q2 2026 revenue and EPS?
Corcept Therapeutics reported revenue of $256.1M and eps of $0.36 for Q2 2026.
Did Corcept Therapeutics beat estimates in Q2 2026?
Revenue beat the consensus estimate of $221.1M by $35.0M. EPS beat the consensus estimate of $0.02 by $0.34.
How did Corcept Therapeutics's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 31.7% from $194.4M a year earlier and eps grew 24.1% from $0.29.
Where can I find Corcept Therapeutics's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001628280-26-050607) and the 10-Q periodic report (0001628280-26-050613) directly on SEC EDGAR. The filing index links above go to sec.gov.